← Back to all trials
Completed
NCT06725342
HNSCC Immuno-genomics Project
Conditions: Molecular Classification of HNSCC
Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Enrollment: 401
Sponsor: Hellenic Cooperative Oncology Group
Summary
For locally advanced and recurrent / metastatic head \& neck squamous cell carcinoma (HNSCC), the is an unmet need for the development of efficient treatment combinations, particularly with immune checkpoint inhibitors. HNSCC have been characterized at the genetic / molecular level concerning characteristics of malignancy and potential clinical actionability ; currently, however, the integration of molecular characteristics of both the malignant cells and the host immune response are considered fundamental for the selection of treatment that best suits these patients .
The primary objective of the NCR-17-12885 project is to classify HNSCC for the selection of optimal therapeutic interventions for the patients, based on genomic characteristics and mutational processes operating in these tumours and on the prevailing activated immune pathways.
Eligibility Criteria
Inclusion Criteria:
-Patients with locally advanced squamous cell carcinoma of the head and neck who were treated with concurrent chemoradiotherapy (CCRT) with or without induction chemotherapy (IC) or radical surgery +/- radiotherapy for laryngeal tumors.
Exclusion Criteria:
* Age \
Source: ClinicalTrials.gov (NCT06725342). StuddyBuddy aggregates publicly available trial information.
